{
  "docId": "019de077-2ede-72aa-ade1-9df6586a5c43",
  "docSlug": "07da8690ded5d079d6760889d2f598d8",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 31 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 31,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide emphasizes the absence of CNS-associated adverse events, which is a key differentiator for this PDE10 inhibitor.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2ede-72aa-ade1-9df6586a5c43/27",
  "deckHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43",
  "deckJsonHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43.json",
  "deckAnchorHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "callout",
      "text": "Primary objective: investigate the safety and tolerability of multiple doses and the effect of food on pharmacokinetic profile of BEN-8744 in healthy volunteers, aged 18-65 years",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29a09df9-6de7-4b1f-a47e-91972ce2209f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Met primary objective\nBEN-8744 was safe and well tolerated, with no Serious Adverse Events (SAEs) reported in any dose cohorts\nImportantly, given liabilities associated with PDE10 inhibitors previously in clinical development for other CNS indications, no evidence of CNS-associated adverse events\nPharmacokinetic profile of BEN-8744 generated suggested twice daily dosing should achieve desired PDE10 target coverage to elicit potential therapeutic effect in subsequent clinical studies in UC patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8778ea4-9e52-43fa-b8f1-f0452af5b1c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "BEN-8744 Phase Ia - positive topline data announced Mar'24",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e7b2e37-9bf2-4714-9508-b88c3b7fc629",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}